2023年8月，《Frontiers in Endocrinology》杂志发表的一篇题为《Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review》的综述填补了空白。作者比较了10种胰高血糖素样肽-1受体激动剂（GLP-1RA...
2023年8月,《Frontiers in Endocrinology》杂志发表的一篇题为《Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review》的...
10.Wysham C, Blevins T, Arakaki R,et al, Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).Diabetes Care. 2...
G.H. 2011. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 96:853-860. ...
11.Htike ZZ, Zaccardi F, Papamargaritis D,et al,Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.Diabetes Obes Metab. 2017;19(4):524. Epub 2017 Feb 17....
Ismail H. Mitha, MD,Milan Zdravkovic, MD, PHD,Maria Düring, PHD,David R. Matthews, MD, and for the LEAD-2 Study Group. (2009). Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes.Diabetes Care,32(1): 84–90....
OBJECTIVETo evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes. DESIGNSystematic review and network meta-analysis. ...
10.Wysham C, Blevins T, Arakaki R,et al, Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).Diabetes Care. 2014 Aug;37(8):2159-67. Epub 2014 May 30 . ...
Comparison of efficacy between different incretin-based therapies; GLP-1 agonists and DPP-4 inhibitors.INTRODUCTIONPHYSIOLOGY OF INCRETINSINCRETIN BASED THERAPIESINCRETIN MIMETICSINCRETIN ENHANCERSCOMPARISON BETWEEN INCRETIN MIMETICS (GLP-1 AGONISTS) AND INCRETIN ENHANCERS (DPP4 INHIBITORS)THE "PROOF OF ...
一 ,GLP-1 受体激动剂发展史及分类 肠促胰 素 (Incretin)是从肠道分泌的可刺激胰 岛素 分泌的物质的统称.1964 年,Elrick 等发[5] 现 "肠促胰素效应 ",即在相同的血糖变化水平下 ,与静 脉注射葡萄糖 相比,口服葡萄糖可引起更多的胰岛 在保留其与 GLP-1 受体结合并发挥生物学效应的 同时使 其不易被 ...